Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 13 Saturday Friday Sunday Monday Tuesday Publication Only MONDAY, JUNE 3 RD 8:00am - 12:00pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 7061 Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study. Lue J Sharman J Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:00am - 12:00pm Hall A Poster 5599 Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial. Pepin JT Pepin JT, McCollum M Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 5554 Final safety results from ATHENA– MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer. O'Malley D Monk B, Buscema J Gynecologic Cancer 9:00am - 12:00pm Hall A Poster 7023 Interim results from the ELiPSE-1 study: A phase 1, multicenter, open- label study of CNTY-101 in subjects with relapsed or refractory CD19- positive B-cell malignancies. Patel K Cross S Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:00am - 12:00pm Hall A Poster TPS6589 Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL). Rotta M Rotta M Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant 9:00am - 12:00pm Hall A Poster TPS7085 Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Ghobadi A Tees M Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia 9:00am - 12:00pm Hall A Poster TPS6586 A first-in-human phase 1, multicenter, open-label study of CB-012, a next- generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify). Daver N Strickland S, Eghtedar A Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant